Patents by Inventor VICTORIA COFRE

VICTORIA COFRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS COMPRISING HETEROCYCLIC RING SYSTEMS AND USES THEREOF
    Publication number: 20190298840
    Abstract: The present invention relates to liquid compositions comprising heterocyclic ring systems that interact with biological molecules through non-covalent interactions. The non-covalent interactions between heterocyclic rings and biological molecules comprise interactions ranging from electrostatic interactions, hydrogen bond interactions, van der Waals interactions, and hydrophobic interactions.
    Type: Application
    Filed: February 11, 2019
    Publication date: October 3, 2019
    Inventors: Mark A. Mitchnick, Bob Becker, Bruce Frank, Victoria Cofre
  • Phenyl-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370336
    Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Victoria Cofre, Antonella Converso, Kevin Rodzinak
  • PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180208557
    Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: July 26, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: VICTORIA COFRE, ANTONELLA CONVERSO, KEVIN RODZINAK